Abstract |
Leukemia is well suited for monoclonal antibody therapy due to the accessible, differentiation antigens that characterize stages of maturation. In this paper, we describe the use of radio-labeled M195, a murine IgG2a, anti-CD33 monoclonal antibody, that can be used to effectively cytoreduce AML cells in relapsed patients when tumor burden is high; or to eliminate minimal residual disease and lengthen disease-free survival in patients with APL in remission. To decrease the likelihood of immunogenicity, a humanized IgG1 version of M195 was constructed that demonstrated a higher avidity and improved effector function than the parent murine antibody. Preliminary results of the first trial in AML using a humanized antibody showed specific bone marrow targeting without an immunogenic response.
|
Authors | P C Caron, D A Scheinberg |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 11 Suppl 2
Pg. 1-6
( 1993)
ISSN: 1042-8194 [Print] United States |
PMID | 8124221
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antigens, CD
- Antigens, Differentiation, Myelomonocytic
- CD33 protein, human
- Cd33 protein, mouse
- Iodine Radioisotopes
- Sialic Acid Binding Ig-like Lectin 3
|
Topics |
- Animals
- Antibodies, Monoclonal
(immunology, therapeutic use)
- Antigens, CD
(immunology)
- Antigens, Differentiation, Myelomonocytic
(immunology)
- Clinical Trials as Topic
- Humans
- Iodine Radioisotopes
(therapeutic use)
- Leukemia, Myeloid, Acute
(radiotherapy)
- Mice
- Radioimmunotherapy
- Sialic Acid Binding Ig-like Lectin 3
|